Evaluation of a convenient vaccination schedule against hepatitis B in HIV-patients with undetectable HIV viral load. Issue 12 (14th March 2018)

• Record Type: Journal Article
• Authors: Kourkounti, Sofia; Retsas, Theodoros; Paparizos, Vassilios; Tsimpidakis, Antonios; Kapsimali, Violetta; Rigopoulos, Dimitrios
• Is Part Of: Vaccine. Volume 36:Issue 12(2018)
• Page Start: 1533
• Page End: 1536
• Publication Date: 2018-03-14
• Subjects: Anti HBs antibody titers -- BMI body mass index -- CI confidence interval -- GMT geometric mean antibody titers -- HAART highly active antiretroviral therapy -- HBV hepatitis B virus -- OR odds ratio; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2018.02.018
• Languages: English
• ISSNs: 0264-410X

Abstract

Highlights: Immune response to 3 doses HBVaxPro 40 mg (0, 1 and 6 months) was 79%. HBVaxPRO caused higher antibody titers compared to standard regimen. 60% of HBVaxPro responders maintained protective antibody titers at month 24. Higher response to HBVaxPro occurred among younger people. The higher dose of HBVaxPro may be a better alternative. Abstract: Vaccination against hepatitis B virus (HBV) is recommended for all HIV-positive individuals but the standard schedule is not satisfactory. High or more doses have also been studied with variable results. We compared a vaccination schedule with a higher dose but fewer shots to the standard scheme (HBVaxPro 40 μg versus Engerix 20 μg at 0, 1, and 6 months). Of the 63 patients vaccinated with HBVaxPro 79%, 65% and 47% seroconverted at month 1, 12 and 24 after vaccination, respectively. A total of 137 patients received Engerix and showed lower response rates (68%, 53% and 38%, respectively). Anti-HBs titers in the Engerix group were also lower with a statistically significant difference. In patients younger than 55 years HBVaxPro was 3 times more likely to provoke a response compared with Engerix (OR = 3, p = 0.006). In conclusion, HBVaxPro 40 μg at 3 doses could be proposed as a more robust and acceptable alternative.